Investigational drug · Phase 3
HR20013
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "HR20013"
First trial start
2024
Sep 3, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HR20013", any sponsor or status.
Conditions studied
As listed on its trial records.
- Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents
Approved drugs for the same conditions: Nausea and vomiting · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "HR20013" as an intervention, largest first.
- Clinical Study of HR20013 for Injection in Patients With Malignant Solid TumorsPivotal-lookingCompleted
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT05509634 · 754 participants · Start Sep 21, 2022 · Primary completion Jun 19, 2023
Drug: HR20013 for injection;dexamethasone; fosaprepitant dimeglumine for injection;palonosetron hydrochloride injection;dexamethasone · For: Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
Sites: Guangzhou, China
- HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer AgentsPivotal-lookingCompleted
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT06554184 · 706 participants · Start Sep 3, 2024 · Primary completion Jul 28, 2025
Drug: HR20013 + dexamethasone + palonosetron placebo; Palonosetron + dexamethasone + HR20013 placebo · For: Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents
Sites: Guangzhou, China
- Fosrolapitant and Palonosetron for Highly Emetogenic ADC-Induced Nausea and Vomiting in Solid TumorsActive, not recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT07841210 · 60 participants · Start Sep 14, 2026 · Primary completion Jan 31, 2028
Drug: Fosrolapitant and Palonosetron; Dexamethasone; Olanzapine; Fosrolapitant and Palonosetron; Dexamethasone · For: Solid Tumor Cancer
Sites: Wuhan, China
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT05465681 · 24 participants · Start Aug 30, 2022 · Primary completion Jan 13, 2023
Drug: HR20013 for injection;dexamethason · For: Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacokinetics, safety, and population pharmacokinetic profiles of Ritanine® in Chinese subjects with impaired or normal liver function: a Phase I trial.
Li Q, Mai J, Wu M, et al. · Front Pharmacol 2026
- HR20013, a fixed-dose intravenous combination of fosrolapitant and palonosetron, for the prevention of cisplatin-induced nausea and vomiting: putting the PROFIT trial into perspective.
Celio L, Antonuzzo A · Ann Palliat Med 2025
- Pharmacokinetics, safety, and efficacy of mixed formulation of fosrolapitant and palonosetron (HR20013) in combination with dexamethasone in patients with solid tumors scheduled for highly emetogenic cisplatin-based chemotherapy: a phase I trial.
Zhao Y, Ma Y, Yin T, et al. · BMC Med 2025
- Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT.
Zhou H, Zhao Y, Zhang M, et al. · J Clin Oncol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.